DKTK School of Oncology Tech Talk
with Prof. Dr. Stefan Knapp
Professor at the Institute for Pharmaceutical Chemistry, Professor and BMLS Research Group Leader at the Buchmann Institute for Life Sciences and CSO of the Structural Genomics Consortium node at the Johann Wolfgang Goethe-University Frankfurt
Wednesday 04.03.26 | 16:00 - 17:00 via Zoom
Join our first DKTK School of Oncology Tech Talk in 2026 with Prof. Dr. Stefan Knapp who will talk about "Development of selective Degraders and their Potential for the Treatment of Cancer". After his presentation there will be ample opportunity to ask questions to the speaker and to engage in a lively discussion.
The human E3 ligase family is a large and diverse family of proteins that has not been widely explored for the development of ligands and selective degraders such as PROTACs (PROtein Targeting Chimeras). In this talk I will discuss strategies for the development of new E3 ligands and the next generation of PROTAC degraders. I will also discuss a streamlined PROTAC synthesis platform using click chemistry in conjunction with a “direct-to-biology” screening approach as well as progress made developing PROTACs into next generation oncology drugs.
SPEAKER
Prof. Dr. Stefan Knapp
Stefan Knapp studied chemistry at the University of Marburg (Germany) and the University of Illinois (USA). He received his Ph.D. in protein crystallography from the Karolinska Institute in Stockholm. He joined Pharmacia (Nerviano, Italy) in 1999 and left the company in 2004 to establish a research group at the Structural Genomics Consortium at the University of Oxford. From 2008 to 2015 he was Professor of Structural Biology at Oxford University (UK) and from 2012 to 2015 Director of Chemical Biology at the Target Discovery Institute at Oxford University. In 2015, he joined the University of Frankfurt as Professor of Pharmaceutical Chemistry. Since 2017, he is also the CSO of the SGC (Structure Genomics Consortium) node at Goethe University Frankfurt. His research interests are the elucidation of molecular/structural mechanisms of kinase regulation using high resolution structures, the design of selective kinase inhibitors, and the inhibition of protein interaction domains including bromodomains, which are the main readers of the epigenetic acetylation code, and E3 ligases, for the development of next generation PROTACs.
VENUE
The Talk will take place online via Zoom.
Registered participants will receive the login information.
ORGANIZER
DKTK School of Oncology for DKFZ
